Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Investor Day (May 2023)

120 slides from Fresenius SE & Co. KGaA's investor day presentation, May 25, 2023

  1. Slide 1: Capital Markets Day 2023

    Capital Markets Day 2023 London, May 25, 2023

  2. Slide 2: Agenda

    Agenda 10:30 – 10:35 Welcome/Opening Remarks Markus Georgi 10:35 – 10:50 #FutureFresenius Michael Sen 10:50 – 11:20 Introduction to Fresenius Kabi & Vision 2026 Pierluigi Antonelli 11:20 – 11:40 Financials & Cross-cutting initiatives Andreas Duenkel 11:40 – 12:10 Q&A 12:10 – 12:20 Coffee Break 12:20

  3. Slide 3: Today's Presenters: Michael Sen

    Today’s Presenters Michael Sen Chairman of the Management Board Fresenius Management SE Michael Sen, became Chairman of the Management Board of Fresenius (equivalent to President and CEO) on October 1, 2022. He joined Fresenius in April 2021 as Chairman of the Management Board of Fresenius Kabi. Bef

  4. Slide 4: Today's Presenters: Antonelli and Duenkel

    Today’s Presenters Pierluigi Antonelli Andreas Duenkel President and CEO Chief Financial Officer Fresenius Kabi Fresenius Kabi Pierluigi Antonelli is the President and CEO of Fresenius Kabi since March 2023. Andreas Duenkel, is Chief Financial Officer at Fresenius Kabi since the beginning of June 20

  5. Slide 5: Today's Presenters: Mahl and Hauer

    Today’s Presenters Dr. Marc-Alexander Mahl Dr. Christian Hauer President Pharma and Nutrition President MedTech Fresenius Kabi Fresenius Kabi Marc Mahl, is the President of Pharma and Nutrition of Fresenius Kabi since May 2023 Christian Hauer, became Member of the Fresenius Kabi Management Board in

  6. Slide 6: Today's Presenters: Schönhofen

    Today’s Presenters Dr. Michael Schönhofen President Biopharmaceuticals Fresenius Kabi Michael Schönhofen, became Member of the Fresenius Kabi Management Board in January 2004, responsible for Operations and Technology. Since then and throughout the years, he has been responsible for different segmen

  7. Slide 7: Slide 7

  8. Slide 8: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to a variety of factors, e.g., changes in business, economic, and compe

  9. Slide 9: Notice on the use of photographs and video recordings

    Notice on the use of photographs and video recordings During this event, photos and video recordings of participants will be made. Some photos and/or recordings may possibly be used for future publication purposes of Fresenius Group and Fresenius Kabi. These include the Fresenius Group and the Frese

  10. Slide 10: #FutureFresenius

    #FutureFresenius

  11. Slide 11: Our mission for #FutureFresenius – Advancing Patient Care

    #FutureFresenius Our mission for #FutureFresenius – Advancing Patient Care © Fresenius SE & Co. KGaA 11

  12. Slide 12: Scale and impact across a broad range of therapies

    #FutureFresenius Scale and impact across a broad range of therapies 30+ studies in parenteral Breakthrough technology Better… and enteral nutrition infusion system Supplying 3 of 7 FDA-  Products 3 multiproduct biologic drug approved cell therapies substance facilities #2 for plasma collection Pipe

  13. Slide 13: Serving fast growing markets along the key paradigm shifts in healthcare

    #FutureFresenius Serving fast growing markets along the key paradigm shifts in healthcare mab assets1 Gene therapy sales mRNA vaccines2 Robotic surgeries3 Data Analytics & AI (in # assets) (in $B) (in # assets) (in M procedures) healthcare sales (in $B) 7 169 1.6 17.2 32 290 1.9 14.1 15.1 74.5 2020

  14. Slide 14: #FutureFresenius – ReSet delivered, now moving to ReVitalize

    #FutureFresenius #FutureFresenius – ReSet delivered, now moving to ReVitalize  FMC deconsolidation on track  New F³ - Fresenius Financial Framework Structural Fresenius Group Operating Companies Investment Companies FSE expectation as major shareholder simplification EBIT margin 14 – 17% 9 – 11% 1

  15. Slide 15: Operating Companies and Investment Companies

    #FutureFresenius #FutureFresenius – Operating Companies and Investment Companies #FutureFresenius Operating Companies Investment Companies Profitability optimization and growth Financial value management Dialysis Project Healthcare products Healthcare services provision business for critically and c

  16. Slide 16: Fresenius Helios – Powerful set of care provision assets

    #FutureFresenius Fresenius Helios – Powerful set of care provision assets Leading healthcare services delivering value for >24 million patients yearly €7.0B €4.4B €0.3B Healthcare products for critically and chronically ill patients • Continuing stable margin delivery • Increased focus on return on

  17. Slide 17: Fresenius Kabi – Accelerating our growth, driving performance

    #FutureFresenius Fresenius Kabi – Accelerating our growth, driving performance Highly specialized, essential healthcare products with balanced market reach €3.8B €2.4B €1.4B €0.2B Healthcare services Pharma Nutrition MedTech Biopharma along the care continuum • Strong focus on key growth vectors • S

  18. Slide 18: Fresenius Kabi – Outstanding customer and manufacturing capabilities

    #FutureFresenius Fresenius Kabi – Outstanding customer and manufacturing capabilities Unique channel access Broad industrial base with Entrepreneurial and customer proximity manufacturing excellence spirit & commitment Trusted partner for our customers Quality and reliability to the benefits of pati

  19. Slide 19: Fresenius Kabi – Consistent, long-term growth driver

    #FutureFresenius Fresenius Kabi – Consistent, long-term growth driver Fresenius Kabi Revenues (€B) Organic growth CAGR +4-7% +4% +6% +6%  >10 years of consecutive organic growth 7.9 6.9 7.0 7.2 6.0 6.0 6.4 6.5 5.0 5.1  Adding ~€1B of Group revenue every ~3 years 2013 2014 2015 2016 2017 2018 2019

  20. Slide 20: Fresenius Kabi – Performance delivery gaining speed

    #FutureFresenius Fresenius Kabi – Performance delivery gaining speed Operating Companies Investment Companies FSE expectation as major shareholder EBIT margin 14 – 17% 9 – 11% 10 – 14% 4 – 6% Organic revenue growth 4 – 7% 3 – 5% EBIT margin (%) Organic revenue growth (%) 17% 7% 14% 4% 17.4 7 7 16.0

  21. Slide 21: Skilled, focused and incentivized management team

    #FutureFresenius Fresenius Kabi – Skilled, focused and incentivized management team Today’s presenters… Marc-Alexander Mahl President, Pharma and Nutrition Pierluigi Antonelli • First joined Fresenius in 2001 • Held management roles in portfolio, development President & Chief Executive Officer and o

  22. Slide 22: Fresenius Kabi – Strong investment thesis

    #FutureFresenius Fresenius Kabi – Strong investment thesis to support #FutureFresenius  Platform business benefitting from new dynamics in healthcare Industry-leading market positions aimed at advancing patient care globally Driver of Group growth based on Vision 2026 strategy Committed to strong m

  23. Slide 23: Introduction to Fresenius Kabi and Vision 2026

    Introduction to Fresenius Kabi and Vision 2026

  24. Slide 24: Highlights of today's meeting

    Introduction to Fresenius Kabi and Vision 2026 Highlights of today’s meeting Financial performance and ambition Portfolio, pipeline, and positioning Strategy and path forward Execution and performance delivery © Copyright Fresenius Kabi AG 24

  25. Slide 25: We are a unique healthcare company

    Introduction to Fresenius Kabi and Vision 2026 We are a unique healthcare company Biopharma > 1M 325 units Fresubin installed base clinical nutrition MedTech of infusion pumps ~ 1.2B consumed each > 400M units minute globally globally of injectable generics sold touched patient lives annually each y

  26. Slide 26: Increased ambitions building on strong performance in Q1

    Introduction to Fresenius Kabi and Vision 2026 Increased ambitions building on strong performance in Q1 Q1 2023 FY 2023 2026 Actuals Guidance Ambition Previous New Organic sales growth 7% Low- to mid- Mid-single 4-7% p.a. p.a. single digit digit 2022-26 % growth EBIT margin % of sales 14.5% ~ 1pp be

  27. Slide 27: Clear path to accelerate value creation

    Introduction to Fresenius Kabi and Vision 2026 Clear path to accelerate value creation Unique portfolio Four • Full-range, system-critical healthcare portfolio complementary business units for • Exciting pipeline with high-value launches essential patient care Attractive fundamentals #1 • Essential,

  28. Slide 28: Full-range provider for essential patient care centered around hospitals

    Introduction to Fresenius Kabi and Vision 2026 Full-range provider for essential patient care centered around hospitals Home Care Long-term care Hospital Pharma Nutrition MedTech Biopharma Outpatient clinics Rehab centers © Copyright Fresenius Kabi AG 28

  29. Slide 29: Full-range provider for essential patient care centered around hospitals

    Introduction to Fresenius Kabi and Vision 2026 Full-range provider for essential patient care centered around hospitals Jasmine (23) Rheumatoid arthritis José (39) Bacterial soft-tissue infection Home Care Long-term care Agatha (83) Swallowing disorder Hospital Pharma Nutrition MedTech Biopharma Mar

  30. Slide 30: Focus on sizeable, attractive and growing healthcare markets

    Introduction to Fresenius Kabi and Vision 2026 Focus on sizeable, attractive and growing healthcare markets Structural Biopharma EBIT margin  Biosimilar market for AIID3 and oncology Market size 2022: ~ €16B1  Critical for cost-pressured healthcare systems CAGR 2022-26: 20-25%  Highly attractive

  31. Slide 31: Portfolio is well positioned for key industry trends

    Introduction to Fresenius Kabi and Vision 2026 Portfolio is well positioned for key industry trends Macroenvironment Key industry trends Therapy Treatment Technology Supporting factors shift shift shift  Demographic shift  Increased treatment volume  Biologics  Homecare  Connected devices  Acc

  32. Slide 32: Strong leading positions across our businesses

    Introduction to Fresenius Kabi and Vision 2026 Strong leading positions across our businesses Pharma Nutrition MedTech Biopharma Overview Hospital-sold generic IV Enteral and Parenteral Stationary drug delivery AIID & oncology biologic Drugs and Fluids Nutrition products and therapy devices drugs (b

  33. Slide 33: Our four complementary businesses are relevant for our customers

    Introduction to Fresenius Kabi and Vision 2026 Our four complementary businesses are relevant for our customers IV Drug units shipped in Essential for treatment of chronically and critically ill patients across treatment settings > 70% US listed on FDA's Essential Medicines List Interlink with one a

  34. Slide 34: We are executing on our Vision 2026 strategy

    Introduction to Fresenius Kabi and Vision 2026 We are executing on our Vision 2026 strategy Broaden Biopharma Growth Expand on MedTech 3 growth vectors Roll out Nutrition Employer of Choice Global Competitiveness Build resilience in Pharma 1 © Copyright Fresenius Kabi AG 34

  35. Slide 35: Unlocking strong growth based on organic and inorganic initiatives

    Introduction to Fresenius Kabi and Vision 2026 Unlocking strong growth based on organic and inorganic initiatives Growth Delivering strong organic sales growth Leveraging synergistic acquisitions Nutrition +4% Commercial excellence, Complementary portfolio rollout of new products, YoY 2021-22 and ge

  36. Slide 36: Driving global competitiveness through efficiency initiatives

    Introduction to Fresenius Kabi and Vision 2026 Driving global competitiveness through efficiency initiatives Global Competitiveness Initiatives driving structural savings Deep dive Innovation and network optimization Footprint & portfolio Process optimization Procurement in Pharma Push targeted dive

  37. Slide 37: Becoming the employer of choice

    Introduction to Fresenius Kabi and Vision 2026 Becoming the employer of choice Employer of Choice Organizational Governance Culture Systems Clear ESG structure & processes & behavior & enabler ambitions Flexible, fit-for-purpose Lean processes and clear Promotion of collaborative State-of-the-art di

  38. Slide 38: Our executive leadership team is incentivized for performance

    Introduction to Fresenius Kabi and Vision 2026 Our executive leadership team is incentivized for performance CEO & CFO Pierluigi Andreas Antonelli Duenkel CEO CFO Business Units Marc-Alexander Christian Michael Mahl Hauer Schönhofen Fully committed to Pharma & Nutrition MedTech Biopharma performance

  39. Slide 39: We focus on clear value drivers across our businesses

    Introduction to Fresenius Kabi and Vision 2026 We focus on clear value drivers across our businesses Bar sizes directional Upper end of Q1 2023 EBIT margin at 14.5% 14-17% EBIT margin band 13.8% EBIT margin Financials Nutrition MedTech Pharma Biopharma EBIT margin 2022 2026 Organic sales growth p.a.

  40. Slide 40: Executing a clear roadmap to reach our 2026 ambition

    Introduction to Fresenius Kabi and Vision 2026 Executing a clear roadmap to reach our 2026 ambition • Expand Nutrition in US, leading with PN • Deliver ~ €440M accumulative savings • Launch next era of • Ramp-up in Wilson & profitable growth vectors Melrose Park • Complete integration of • Launch bi

  41. Slide 41: Clear path to performance delivery ahead

    Introduction to Fresenius Kabi and Vision 2026 Clear path to performance delivery ahead Strong Q1 2023 and increased short- and mid-term guidance Compelling value creation plan across all BUs with focus on disciplined execution to accelerate performance Executive team with clear accountabilities and

  42. Slide 42: Financials & Cross-cutting initiatives

    Financials & Cross-cutting initiatives

  43. Slide 43: Focus on Financials and cross-cutting initiatives

    Financials and cross-cutting initiatives Focus on Financials and cross-cutting initiatives Bar sizes directional Andreas Duenkel 20 minutes Upper end of 14-17% EBIT margin band 13.8% EBIT margin Financials Nutrition MedTech Pharma Biopharma EBIT margin 2022 2026 © Copyright Fresenius Kabi AG 43

  44. Slide 44: CFO agenda: clear focus on value creation & returns

    Financials and cross-cutting initiatives CFO agenda: clear focus on value creation & returns Kabi ambition for 2026 1 Increase focus & transparency Organic sales growth p.a. 4-7% 2 Drive structural productivity EBIT margin 14-17% 3 Improve capital efficiency & returns Upper end of EBIT margin band b

  45. Slide 45: New reporting structure enables better decision-making

    Financials and cross-cutting initiatives New reporting structure enables better decision-making 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns Sales & EBIT in 3+1 Structure Growth Vectors MedTech Nutrition Biopharma Pharma IV Drugs & Sales (in

  46. Slide 46: Kabi portfolio with strong potential

    Financials and cross-cutting initiatives Kabi portfolio with strong potential 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns Sales 2022 (in €M) EBIT 2022 (in €M) YoY Organic sales growth EBIT margin 107% 3% 8.5% 13.8% 4% 188 -28 2.374 339 4% 20

  47. Slide 47: Targeted actions benefit 2023 EBIT performance

    Financials and cross-cutting initiatives Targeted actions benefit 2023 EBIT performance 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns Key drivers Around 13.8% 2 Drive structural productivity 14% EBIT margin Volume Price / Mix Cost increase Cos

  48. Slide 48: Acceleration of measures to drive 2023 performance

    Financials and cross-cutting initiatives Acceleration of measures to drive 2023 performance 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns Cost inflation vs. pricing development Price / Mix Effect Cost inflation expected to persist but Index Co

  49. Slide 49: Structural cost savings to drive performance

    Financials and cross-cutting initiatives Structural cost savings to drive performance 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns 1 Footprint & portfolio 2 Process optimization 3 Procurement Further potential €440M structural identified Targ

  50. Slide 50: Assets largely in place for future growth: lower capex ahead

    Financials and cross-cutting initiatives Assets largely in place for future growth: lower capex ahead 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns Increased focus on cash & capital efficiency Capex in €M (in % sales) High historic capex level

  51. Slide 51: Inventory optimization as part of capital efficiency focus

    Financials and cross-cutting initiatives Inventory optimization as part of capital efficiency focus 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns Measures initiated to improve net working capital Inventory (in €M) & Inventory in % of Sales (in

  52. Slide 52: Capital efficiency focus will untap full potential

    Financials and cross-cutting initiatives Capital efficiency focus will untap full potential 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns CCR1 (times) ROIC2 (in %) 0.9 0.7 0.7 8.5% 8.8% 7.8% 2020 2021 2022 Ambition 2020 2021 2022 Ambition 2026

  53. Slide 53: After a strong Q1 2023 we are confident on the 2023 outlook

    Financials and cross-cutting initiatives After a strong Q1 2023 we are confident on the 2023 outlook 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns Previous Updated Target range Status Q1 2023 Guidance 2023 Guidance 2023 Organic Low- to mid-sin

  54. Slide 54: New disclosure and financial ambition 2026

    Financials and cross-cutting initiatives New disclosure and financial ambition 2026 1 Increase focus & transparency 2 Drive structural productivity 3 Improve capital efficiency & returns  Verticals allow for end-to-end steering Organic sales growth EBIT margin EBIT development p.a. 2022-26 ambition

  55. Slide 55: Committed to deliver our financial targets for 2026

    Financials and cross-cutting initiatives Committed to deliver our financial targets for 2026 Kabi ambition for Organic sales growth EBIT margin 2026 Organic sales growth p.a. 7% 17% Target 4-7% Target range range 14% 4% EBIT margin 14-17% 2022 Q1 Ambition 2023 2026 2022 Q1 Ambition 2023 2026 Upper e

  56. Slide 56: Focus on Nutrition

    Focus on Nutrition

  57. Slide 57: Nutrition

    Nutrition Nutrition Bar sizes directional Marc-Alexander Mahl 30 minutes Upper end of 14-17% EBIT margin band 13.8% EBIT margin Financials Nutrition MedTech Pharma Biopharma EBIT margin 2022 2026 © Copyright Fresenius Kabi AG 57

  58. Slide 58: Nutrition business at a glance

    Nutrition Nutrition business at a glance Parenteral Nutrition Enteral Nutrition Feeding of nutritional products intravenously, Delivery of nutrients via the GI-tract, Agatha (83) bypassing the GI-tract1 orally administered, or via a tube Diagnosis Swallowing disorder after radiotherapy with cancer s

  59. Slide 59: Nutrition: World-class business getting even better

    Nutrition World-class business getting even better Sales YoY organic growth 2021–22: 4% (Q1 2023: 8%) Fundamentally attractive markets with strong growth dynamic and accretive margin profile Sales in €B 4–7% p.a.1 2.2 2.4 Bar sizes indicative Leading portfolio driven by innovation; extended into gro

  60. Slide 60: Nutrition – Fundamentally attractive market

    Nutrition Nutrition – Fundamentally attractive market ~ €10B Demographic developments ~ 6% Growth in elderly population, chronic-disease CAGR prevalence, and surgical procedures ~ €6B Rise of Homecare Enteral Expansion of the Homecare and out-of- Nutrition hospital segments for clinical nutrition Nu

  61. Slide 61: Global leader in Parenteral Nutrition

    Nutrition Global leader in Parenteral Nutrition Parenteral Nutrition Enteral Nutrition Position by major geography Position by major geography Global market #1 Global market #4 #2 Not addressed #1 #2 #1 #2 #1 #3 = North America (excl. compounding business) = Europe = China = Latin America and Asia-P

  62. Slide 62: Innovating Nutrition since 1962

    Nutrition Innovating Nutrition since 1962 Future launches 7+ Launch of SmofKabiven, Omegaven launch Peditrace Novum, Launches over the innovative 3- first 3CB including in US - emulsion upcoming launch for next 3 years chamber-bag SMOF/ n3-FA with high share of the smallest patients planned fish oil

  63. Slide 63: Expanding our leading portfolio in Parenteral Nutrition

    Nutrition Expanding our leading portfolio in Parenteral Nutrition We offer the most comprehensive portfolio in PN Constant product innovation Benchmarking of relevant PN sub-segments (sample) • > 15 ongoing clinical studies in PN, ~ 10 more in preparation Competitor Competitor Competitor Competitor

  64. Slide 64: Offering strong products in Enteral Nutrition

    Nutrition Offering strong products in Enteral Nutrition Selected examples Highly differentiated portfolio in EN Portfolio highlights • Broad portfolio to address individual customer needs and preferences • Strong growth trajectory (> 10% CAGR 2020-22) Wide variety of styles & tastes High energy & pr

  65. Slide 65: We are creating awareness and expanding the Nutrition market

    Nutrition We are creating awareness and expanding the Nutrition market Nutrition integral for clinical care We support healthcare professionals and communities We work with partners in Latin America, Europe, and Asia to undertake research, create hospital patients worldwide is awareness, and educate

  66. Slide 66: Most integrated portfolio across channels

    Nutrition Most integrated portfolio across channels Fresenius Kabi portfolio Clinical nutrition MedTech Nutritional service Leading nutritional State of the art Digital & on-site products nutritional pumps support services > 20% of our sales are generated in the Homecare segment Products to manage C

  67. Slide 67: Succeeding in the growing Homecare segment

    Nutrition Succeeding in the growing Homecare segment Homecare is key in nutrition Fresenius Kabi is a leader in the Homecare segment Homecare is on the rise globally both in EN and PN General underlying shift towards Active in Homecare outpatient settings Not active in Homecare Rising awareness of h

  68. Slide 68: Strong operational network leveraging global scale

    Nutrition Strong operational network leveraging global scale Production unit and R&D network Setup highlights Uppsala/Brunna  Globally scaled Bad Homburg R&DC Germany production network of five state of the art plants Beijing  Four powerful R&D hubs Wuxi with optimized geo footprint R&DC Austria 

  69. Slide 69: Plans to further unlock growth opportunities in China

    Nutrition Plans to further unlock growth opportunities in China China is a crucial market for nutrition FSMP – A potential new attractive and we have a leading position segment in which we are well positioned  We are #1 in PN with double-digit market share  Emerging segment initiated by recent reg

  70. Slide 70: We aim to offer a comprehensive PN portfolio in US

    Nutrition We aim to offer a comprehensive PN portfolio in US Most of PN market 2 Future currently not addressed Total US PN market 2022 Bringing a full portfolio to the US ~ €0.8B 1 Today 1  Addressing ~70% of US PN market1 Addressed ~20% We have greatly expanded our position in recent years  Cros

  71. Slide 71: Nutrition: World-class business getting even better

    Nutrition World-class business getting even better Sales YoY organic growth 2021–22: 4% (Q1 2023: 8%) Fundamentally attractive markets with strong growth dynamic and accretive margin profile Sales in €B 4–7% p.a.1 2.2 2.4 Bar sizes indicative Leading portfolio driven by innovation; extended into gro

  72. Slide 72: Focus on MedTech

    Focus on MedTech

  73. Slide 73: MedTech

    MedTech MedTech Bar sizes directional Christian Hauer 30 minutes Upper end of 14-17% EBIT margin band 13.8% EBIT margin Financials Nutrition MedTech Pharma Biopharma EBIT margin 2022 2026 © Copyright Fresenius Kabi AG 73

  74. Slide 74: MedTech business at a glance

    MedTech MedTech business at a glance Illustrative Our portfolio (sample) Maria (62) Transfusion Medicine & Cell Infusion & Nutrition Systems Therapies (TCT) (INS) Diagnosis Cancer Broad portfolio of products for blood collection and Drug delivery devices, e.g., infusion pumps, IV blood processing in

  75. Slide 75: Driving performance and value in MedTech

    MedTech Driving performance and value in MedTech Sales Leading TCT position with strong growth segments YoY organic growth 2021–22: 4% (Q1 2023: 9%) Plasma and Cell & Gene Therapy (CGT) Sales in €B 8-10% p.a.1 1.3 1.4 Strong infusion business with additional momentum Bar sizes indicative from Ivenix

  76. Slide 76: Leader in blood collection and growth in Plasma and CGT

    MedTech Leader in blood collection and growth in Plasma and CGT Transfusion Medicine & Cell Therapies Sub- Market Market Position by major geography segments Customers (excerpt) size in €B growth 1.4 Global market #2 Blood collection NAM #1 0.8 Plasma #2 0.6 EMEA Cell & Gene Therapy RoW #2 0.7 Hospi

  77. Slide 77: Positioning MedTech for performance today and tomorrow

    MedTech Positioning MedTech for performance today and tomorrow TCT segment Segment attractiveness MedTech strategy − #1 in blood collection globally Defend and expand Blood − MedTech's strongest and biggest segment global market-leading collection position BPU1 − Stable and continuous market growth

  78. Slide 78: Innovation drives sales and margins

    MedTech Innovation drives sales and margins Cue, a new-generation small- Net sales from new product launches €M volume cell processing device Bar sizes indicative Recent product ~ 40% launches with Amicus Blue to enhance ECP1 CAGR capabilities above average margins Lovo, a cutting-edge cell washing

  79. Slide 79: Replicating the TCT success story in Infusion & Nutrition Systems

    MedTech Replicating the TCT success story in Infusion & Nutrition Systems Operational setup for TCT as E2E unit … … achieved tangible outcomes Initiated to improve performance delivery > 6% ~ 4pp  Ensuring customer proximity 2016–21 2016–21  Strengthening accountability Global sales Gross profit C

  80. Slide 80: Targeting a market leading position in the US

    MedTech Targeting a market leading position in the US Infusion & Nutrition Systems US IV therapy, a highly attractive market Position by major geography Global market #5  ~ €4B market for IV therapy  ~ 4% mid-term market growth expected  Unique workflow and interoperability #2 requirements LATAM

  81. Slide 81: Ivenix is a game changer for our INS business in the US

    MedTech Ivenix is a game changer for our INS business in the US Seamless interoperability Built-in integration with EMR devices Reduced infusion-related errors Smartphone-like touch display and guided workflows Reduced total cost of ownership Advanced efficiency estimated at 40% in savings Accurate

  82. Slide 82: Building a unique infusion ecosystem with Ivenix

    MedTech Building a unique infusion ecosystem with Ivenix IV fluids with Leading high- DEHP-free Advanced, market- precision containers and infusion pump self-sealing leading products ports Interoperability/ Strong contract Leading-edge EMR1 integration/ infusion bundling offering auto programming di

  83. Slide 83: Delivering a margin-accretive $200M+ IV therapy business by 2026

    MedTech Delivering a margin-accretive $200M+ IV therapy business by 2026 IV therapy sales ambition Achievements to date Glowing review by KLAS (A+ in 3 of 4 categories) GPO-awarded “innovative technology" Strong double-digit sales growth p.a. GPO-awarded "breakthrough technology" 10 providers alread

  84. Slide 84: Improving our global manufacturing/assembly network

    MedTech Improving our global manufacturing/assembly network Setup highlights Production sites  Contingency and customer proximity within plant network Emmer- Compascuum  > €200M investment in leading-edge plants in the La Châtre Błonie Friedberg last 5 years for automation, capacity increase, tran

  85. Slide 85: Improving our operational performance worldwide

    MedTech Improving our operational performance worldwide Production network Objective Next steps Savings Advantages Emmer-Compascuum TCT disposable Mirandola  Transfer TCT's transfer finished Low- disposable production from E.-Co. to Haina Q2 '24 double- Haina Dominican Republic  Insourcing of Iven

  86. Slide 86: Expanding into new, highly attractive data-based business

    MedTech Expanding into new, highly attractive data-based business Highlights Fresenius Kabi's software sales growth  High EBIT margin in software  High value add (patient safety/process efficiency) for device > 70% users (i.e., nurses, pharmacists, healthcare professionals) CAGR  INS: Vigilant So

  87. Slide 87: Driving performance and value in MedTech

    MedTech Driving performance and value in MedTech Sales Leading TCT position with strong growth segments YoY organic growth 2021–22: 4% (Q1 2023: 9%) Plasma and CGT Sales in €B 8-10% p.a.1 1.3 1.4 Strong infusion business with additional momentum Bar sizes indicative from Ivenix Rigorous focus on fur

  88. Slide 88: Focus on Pharma

    Focus on Pharma

  89. Slide 89: Pharma

    Pharma Pharma Bar sizes directional Marc-Alexander Mahl 30 minutes Upper end of 14-17% EBIT margin band 13.8% EBIT margin Financials Nutrition MedTech Pharma Biopharma EBIT margin 2022 2026 © Copyright Fresenius Kabi AG 89

  90. Slide 90: Pharma business at a glance

    Pharma Pharma business at a glance Our portfolio (sample) José (39) IV Drugs IV Fluids Intravenously administered drugs in vials, syringes, Intravenously administered or ampoules for different purposes standard solutions and fluids Diagnosis Bacterial soft-tissue infection after traumatic injury Ane

  91. Slide 91: Consistent, stable value generation – in the past and in the future

    Pharma Consistent, stable value generation – in the past and in the future Sales Full-range supplier for system-critical IV Drugs and YoY organic growth 2021–22: 1% (Q1 2023: 3%) Fluids with leading positions across geographies Sales in €B 2-4% p.a.1 3.8 Bar sizes indicative Strong footprint in attr

  92. Slide 92: Essential products, mature market with headwinds and tailwinds

    Pharma Essential products, mature market with headwinds and tailwinds ~ €50B Demographic developments Supportive volume trends through rise in 2-3% population and chronic-disease prevalence ~ €44B CAGR Global growth trends Developing markets across the globe with increasing access to healthcare IV D

  93. Slide 93: Case study: Propofol supplied through COVID-19 crisis

    Pharma Case study: Propofol supplied through COVID-19 crisis COVID-19 disrupted Propofol demand Kabi supplies, when others struggle Anesthesia treatments skyrocketed with Illustrative Propofol production output in mg at Graz production site ventilation needs due to COVID-19 outbreak Propofol is #1 u

  94. Slide 94: Leading our addressed markets in major geographies

    Pharma Leading our addressed markets in major geographies IV Drugs IV Fluids Position by major geography Position by major geography Global market #1 Global market #3 #2 Emerging market for FK #1 #1 #6 #3 = North America = Europe = Latin America and Asia-Pacific (excl. Japan) = Fresenius Kabi = Comp

  95. Slide 95: Differentiated and broad Gx portfolio – a one-stop-shop for customers

    Pharma Differentiated and broad Gx portfolio – a one-stop-shop for customers 80% of relevant LoEs covered1 Well-positioned to succeed in the future LoE coverage 2023-40 #1 portfolio with > 160 IV Drugs in the US Non-covered 15 200 150 2021 2022 2023 > 70% LoEs (~ 20%) Representing a ~ €30B of the un

  96. Slide 96: Differentiation through product upgrades and pre-filled product range

    Pharma Differentiation through product upgrades and pre-filled product range We continuously upgrade our Our pre-filled products yield significant benefits products in … Pre-filled syringes Strength Improved safety Different dosage strength to become product of choice for select indications Ease of

  97. Slide 97: Committed to the needs of US customers

    Pharma Committed to the needs of US customers Melrose Park, Illinois Expansion highlights Setup for success  Multiproduct fill-finish facility Close collaboration > €400M  One cytotoxic line and with the FDA in recurring review cycles Capex invested in expansion in the one high-potency line past f

  98. Slide 98: Global operations network with regional footprint for reliable supply

    Pharma Global operations network with regional footprint for reliable supply Commercial setup with Production sites Regional sites Global sites global scale & local reach Louviers Friedberg Vilassar Melrose Park Labesfal Halden Kutno > 125 markets served Grand Island across the Isola della globe Wil

  99. Slide 99: Driving excellence and streamlining of our operations

    Pharma Driving excellence and streamlining of our operations Overall manufacturing improvements OEE1 in % +3 pps Louviers > €50M Produce same capacity p.a. on 2 vs. 3 lines COGS advantage of 10-30% per unit of Vision 2026 savings 2020 2021 2022 in the coming years Leading-edge digital monitoring tec

  100. Slide 100: Consistent, stable value generation – in the past and in the future

    Pharma Consistent, stable value generation – in the past and in the future Sales Full-range supplier for system-critical IV Drugs YoY organic growth 2021–22: 1% (Q1 2023: 3%) and Fluids with leading positions across geographies Sales in €B 2-4% p.a.1 3.8 Bar sizes indicative Strong footprint in attr

  101. Slide 101: Focus on Biopharma

    Focus on Biopharma

  102. Slide 102: Biopharma

    Biopharma Biopharma Bar sizes directional Michael Schönhofen 30 minutes Upper end of 14-17% EBIT margin band 13.8% EBIT margin Financials Nutrition MedTech Pharma Biopharma EBIT margin 2022 2026 © Copyright Fresenius Kabi AG 102

  103. Slide 103: Biopharma business at a glance

    Biopharma Biopharma business at a glance Illustrative Our portfolio Jasmine (23) Biosimilars and CDMO Biosimilars (biologic drugs with proven similarity to a patent-expired compound) as well Diagnosis Rheumatoid arthritis as contract development and manufacturing services (CDMO) for other clinical a

  104. Slide 104: Aiming for powerful sales and margin performance

    Biopharma Aiming for powerful sales and margin performance Sales Investments in Biosimilars starting to pay off; YoY organic growth 2021-22: 107% (Q1 2023: 57%) track record of successful market entries Sales in €B 3–4× Bar sizes indicative Strong AIID/oncology portfolio and pipeline; ambition to ou

  105. Slide 105: Established as a global biopharma player

    Biopharma Established as a global biopharma player 10+ €0.2B Pipeline assets Foundation Global launches: US launches: Tyenne, SwissBioSim ustekinumab, Stimufend, GmbH1 Acquisition Annual Biopharma Idacio rituximab of majority revenues Idacio stake in global launched in biosimilars and Launched 1st >

  106. Slide 106: Aiming to outgrow the market with a strong portfolio

    Biopharma Aiming to outgrow the market with a strong portfolio Sub- Market size Kabi's medium-term ambition and Segments segments and growth1 Market highlights growth rationale Autoimmune and €70B+ market of AIID  Strong market entry position in global inflammatory biologics with upcoming key marke

  107. Slide 107: Expanding our footprint with a broad pipeline of assets

    Biopharma Expanding our footprint with a broad pipeline of assets Indicative biosimilar sales development Pre-clinical Clinical Approved/marketed Bar sizes illustrative Rituximab 3–4× Ustekinumab Denosumab AV01 AV02 FKS730 FKSXXXX FKSXXXX (2) Bevacizumab €0.2B Rituximab MB05 MB09 MB12 MB04 MB03 MB11

  108. Slide 108: Delivering commercial success in the US with a strong launch setup

    Biopharma Delivering commercial success in the US with a strong launch setup Originator BioS On Molecule Sales 22 LoE Uptake1 Status Launch highlights track ~ €21.2B  FDA approved  Competitive offering in variety of application forms (~ €19B US sales) 2023 66%2  Expected launch Jul 2023  Highest

  109. Slide 109: Engaging through comprehensive omnichannel & digital capabilities

    Biopharma Engaging through comprehensive omnichannel & digital capabilities Full personal and non-personal promotion Channel enablement  Payer and access  Media/digital drivers communication tool  Direct rep. triggered  Interactive visual sales e-mails  Medication instructions of use video  HC

  110. Slide 110: International markets hold strong growth opportunities

    Biopharma International markets hold strong growth opportunities We delivered against expectations and are positioned to Leveraging proven succeed in international markets beyond Idacio go-to-market expertise From Idacio's success… …to success across biosimilars Established relationships with releva

  111. Slide 111: Unlocking synergies from complementary know-how and skills

    Biopharma Unlocking synergies from complementary know-how and skills Pharma value chain Integrated biopharma A offering based on Drug Immunology Oncology vertical integration Complementary development focus focus B Biosimilars  Immunology  Oncology Drug Currently network State of the art biologic-

  112. Slide 112: Evolving our in-house operations network

    Biopharma Evolving our in-house operations network Production unit and R&D network Setup highlights  Securing supply León reliability and sustainability with insourcing of value chain Garin  Leading-edge production Eysins Munro with multiple lines for drug substance  Capacity availability CMO pro

  113. Slide 113: Progressing vertical integration

    Biopharma Progressing vertical integration Steps along the value chain Status of integration1 Value outlook A B Drug substance Technology transfer Drug manufacturing substance API synthesis, purification from Merck KGaA > 30% manufacturing to mAbxience ongoing1 and formulation, quality control C Dru

  114. Slide 114: Aiming for powerful sales and margin performance

    Biopharma Aiming for powerful sales and margin performance Sales Investments in biosimilars starting to pay off; YoY organic growth 2021-22: 107% (Q1 2023: 57%) track record of successful market entries Sales in €B 3–4× Bar sizes indicative Promising AIID/oncology portfolio and pipeline; ambition to

  115. Slide 115: Key take aways

    Key take aways

  116. Slide 116: Three key messages to take home from today

    Fresenius Kabi summary Three key messages to take home from today Strong Q1 2023 and increased short- and mid-term guidance Compelling value creation plan across all BUs with focus on disciplined execution to accelerate performance Executive team with clear accountabilities and performance focus © C

  117. Slide 117: Delivering on our financial ambitions to 2026

    Fresenius Kabi summary Delivering on our financial ambitions to 2026 Kabi performance in Q1 2023 Broaden Biopharma 7% Organic sales growth 14.5% EBIT margin Expand on MedTech Kabi outlook for 2023 Mid single digit Organic sales growth Roll-out Nutrition Around 14% EBIT margin Kabi ambition for 2026

  118. Slide 118: Appendix

    Appendix

  119. Slide 119: Glossary

    Glossary AA Amino acids FDA Food and Drug Administration mRNA Messenger ribonucleic acid AIID Autoimmune inflammatory disease FSE Fresenius SE OBI On-body injector API Active pharmaceutical ingredient FSMP Food for special medical purposes OEE Overall equipment effectiveness BPU Blood pack unit GI-t

  120. Slide 120: Fresenius

    = FRESENIUS

Fresenius SE & Co. KGaA — Investor Day (May 2023) on 6ix